Hemophilia Prophylaxis in the Era of Non-Factor Therapies Check out our extensive video library (see channel for our latest videos) Abstract Hemophilia treatment has changed dramatically with the introduction of non-factor therapies. This paper examines how these new treatments affect prophylactic care for
Tag: hemophilia
Gene Therapy Breakthrough: New Evidence Shows Promise for Hemophilia Cure
Valoctocogene Roxaparvovec Gene Therapy Success Detailed For Hemophilia A Patients
Valoctocogene Roxaparvovec Gene Therapy Success Detailed For Hemophilia A Patients Overview Valoctocogene roxaparvovec is a gene therapy utilizing an adeno-associated virus serotype 5 (AAV5) vector, approved for treating severe hemophilia A (HA). The purpose of this summary is to present the safety and efficacy outcomes observed seven years post-dosing in a phase
